Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCI 1124

Next Previous
Drug Profile

BCI 1124

Alternative Names: BCI-1124; Dual CSF1R/FLT3 inhibitor - BCI Pharma

Latest Information Update: 03 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BCI Pharma
  • Developer BCI Pharma; University of Bergen
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 19 Jun 2024 BCI Pharma has been acquired by Gedeon Richter
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in France
  • 04 Sep 2019 BCI 1124 is available for licensing as of 04 Sep 2019. http://www.bci-pharma.com/?page_id=972

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top